Obesity

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes
Events & Education
Practical Updates in Primary Care

FDA Alerts

FDA Alert
shutterstock
FDA Alert
FDA Approves Semaglutide For Reducing Serious Cardiovascular Events Among Adults With Heart Disease and Obesity, Overweight
03/21/2024

Anthony Calabro, MA

Anthony Calabro, MA
On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
03/21/2024
FDA Alert
fda
FDA Alert
Tirzepatide Gains FDA Approval for Chronic Weight Management
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023
Obesity
Obesity
FDA Issues Warning of Gastric Balloon-Related Deaths
08/11/2017
In response to several reported deaths, the FDA has issued a warning to alert health care providers of potential mortality risk related to intragastric balloon systems.
08/11/2017
Obesity
Obesity
FDA Advisory Panel: Obesity and Hypoparathyroidism Drugs Receive Nod of Approval
09/15/2014
The FDA has approved several new drugs that medical professionals should be aware of.
09/15/2014